A patient with agranulocytosis following the discontinuation of methimazole treatment for 4 months: A case report
نویسندگان
چکیده
Agranulocytosis is a rare and serious adverse effect of antithyroid drugs (ATD), in particular methimazole (MMI), and usually develops within 3 months following the start of uninterrupted ATD treatment. Agranulocytosis may also develop for the first time following interruption and subsequent resumption of the same ATD treatment. In this case report, a 27-year-old female, who was treated for thyrotoxicosis with MMI, developed agranulocytosis following the discontinuation of MMI treatment for four months. To the best of our knowledge, this is the first study to report this. The aim of this report is to increase the awareness of physicians of the onset of agranulocytosis when MMI is discontinued, and to demonstrate that MMI should be used with caution.
منابع مشابه
Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case
Agranulocytosis is a rare and critical adverse effect of antithyroid drugs (ATD). The occurrence of agranulocytosis in continuous ATD treatment patients is well known; however, a case of ATD agranulocytosis occurring following the discontinuation of methimazole (MMI) treatment is not a usual situation. We herein describe a case of a 41-year-old woman who was previously administered methimazole ...
متن کاملArthritis Associated With Low Dose Methimazole Therapy: A Case Report.
Here in this paper, we report a 31-year-old case admitted with symptoms of hyperthyroidism that was then diagnosed with Grave's disease (GD) and underwent treatments with a low dosage of methimazole (10 mg/day). 20 days after treatments initiations, she developed antithyroid arthritis syndrome. This patient experienced arthritis and arthralgia in at least 4 joints. And all autoimmune and microb...
متن کاملSudden onset agranulocytosis and hepatotoxicity after taking methimazole.
Agranulocytosis is a rare adverse effect of methimazole. The usual duration of treatment prior to the onset of agranulocytosis is approximately 1 to 4 months, and can be as long as 1 year. Agranulocytosis together with hepatotoxicity is an extremely rare idiosyncratic side effect of methimazole treatment. We present an unprecedented case of a Grave's disease patient who showed a strong reaction...
متن کاملCase Report Massive plasmacytosis with severe marrow suppression induced by methimazole in Graves’ disease patients: case report and literature review
Antithyroid drugs (ATDs) induced leukopenia is commonly seen, but life-threatening agranulocytosis is a rare occurrence. Interestingly, agranulocytosis accompanied with plasmacytosis in bone marrow (BM) is rarer. In this study, we admitted a patient with Graves’ disease who had been treated with 15 mg/d methimazole (MMI) for 42 days. She presented with agranulocytosis and plasmacytosis in bone ...
متن کاملUnusual Synchronous Methimazole-Induced Agranulocytosis and Severe Hepatotoxicity in Patient with Hyperthyroidism: A Case Report and Review of the Literature
Context. To report a patient with hyperthyroidism who developed concurrent occurrence of agranulocytosis and severe hepatotoxicity after taking methimazole (MMI). Case. A 51-year-old Chinese male was diagnosed as hyperthyroidism with normal white blood count and liver function. After 4 weeks' treatment with MMI 20 mg/d, it developed to agranulocytosis and severe cholestatic hepatotoxicity. The ...
متن کامل